A breast cancer treatment developed by Australian researchers has successfully halted tumour growth for twice as long as previously recorded, it was announced on Friday.
The therapy involves taking a new class of drug, called CDK4 and CDK6 inhibitors, and it significantly delayed tumour growth in patients with advanced breast cancer.
Research:
- Researchers from the Peter MacCallum Cancer Centre (PMCC).
- They will now trial the therapy in patients with early-stage cancer.
- Furthermore,in an attempt to stop the disease from spreading throughout the body.
- The tablets, Palbociblib, Ribociclib and Abemaciclib.
- Work differently to hormone treatments currently used by deactivating the process that allows cancer cells to grow uninhibited.
- Richard de Boer, an oncologist at the PMCC and Epworth hospital.
- Said that developing a tablet that has no side effects such as the inhibitors was an “exciting” step.
- “We’ve got good chemotherapy drugs, but they’re toxic.
- They require intravenous treatment, you lose your hair and you can feel really sick,” de Boer told on Friday.
- “If you can come up with a combination treatment that delays the need for chemotherapy by 10, 20 or 30 months, that’s a great achievement for women with advance disease.”
- More than 4,600 women will participate in the new global trial of Palbociblib.
- In addition,where the new drug’s ability to stop cancer from returning after surgery.
- In addition,chemotherapy and radiation will compared to standard hormone therapy.